GmmaTech

Interpace Diagnostics Group stock (IDXG) is down: expect recover

NASDAQ:IDXG   None
There are some positive commercial developments for the company. The mega-insurer Cigna stated it will cover ThyraMIR, a microRNA gene expression classifier for thyroid nodules, that Interpace Diagnostics developed.

The health insurer has covered another IDXG's drug ThyGenX since 2017. 80% of ThyGenX orders are coupled with an order for ThyraMIR, and the two tests are billed independently.

www.finstead.com/bit...diction-july-25-2018


Pernyataan Penyangkalan

Informasi dan publikasi tidak dimaksudkan untuk menjadi, dan bukan merupakan saran keuangan, investasi, perdagangan, atau rekomendasi lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Persyaratan Penggunaan.